Picture courtesy The Indian Express
Pune: Serum Institute of India (SII) has sought emergency use authorisation (EUA) for its COVID-19 vaccine Covovax for the 12-17 age group.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, stated in the application that data from two studies on 2,707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, The Indian Express reported quoting official sources.
The Drugs Controller General Of India (DCGI) has already approved Covovax for emergency use among adults.
Covovax is produced in India by Pune-based Serum Institute through technology transfer from American biotechnology company Novavax.
Earlier today, DCGI granted emergency use approval to Biological E’s indigenous vaccine Corbevax for children aged 12 to 17 years.
Currently, only those in the 15-17 year age group are being inoculated in India.
Bhubaneswar: The Odisha Human Rights Commission (OHRC) has sent notices to Secretaries of Food &…
New Delhi: Even as his recently-released horror comedy ‘Bhool Bhulaiyaa 3’ continues to mint money…
New Delhi/Bhubaneswar: After over 20 days of investigation and analysing more than 700 CCTV cameras,…
New Delhi: The Delhi High Court has closed proceedings on a petition challenging the Rajiv…
Mumbai: ‘12th Fail’ actor Vikrant Massey recently got trolled after pictures of him touching his…
Mumbai: Mumbai Police swung into action immediately after Bollywood superstar Shah Rukh Khan received a…
Dubai: The effects of global climate change are being seen in various manifestations across the globe.…
Mumbai: When criminals are idolised and used for commercial purposes, police are bound to take action.…